MedTrace Logo

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

NCT05873686 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-03-03

No results posted yet for this study

Summary

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Conditions

  • Advanced Solid Tumor
  • NSCLC (Non-small Cell Lung Cancer)
  • Renal Cancer
  • Mesothelioma
  • Non-Small Cell Squamous Lung Cancer
  • Non-small Cell Lung Adenocarcinoma

Interventions

DRUG

NXP900

NXP900 is an orally administered SRC/YES1 kinase inhibitor

Sponsors & Collaborators

  • Nuvectis Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Udai Banerji, Prof · Institute of Cancer Research, Royal Marsden NHS Foundation Trust

  • Gerald Falchook, MD · Sarah Cannon Cancer Institute, HealthOne Denver

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2027-03-31
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05873686 on ClinicalTrials.gov